Company Filing History:
Years Active: 2014
Title: Zhe-Sheng Chen: Innovator in Cancer Treatment
Introduction
Zhe-Sheng Chen is a notable inventor based in Belle Mead, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and patenting efforts. His work focuses on addressing the challenges of multidrug resistance in cancerous cells.
Latest Patents
Zhe-Sheng Chen holds a patent for the "Use of phosphodiesterase inhibitors for treating multidrug resistance." This invention relates to methods of treating multidrug resistance in cancerous cells using phosphodiesterase (PDE) inhibitors, particularly PDE5 inhibitors. The patent outlines methods for treating multidrug resistance that may arise during the administration of chemotherapeutic agents. It also discusses the use of PDE5 inhibitors in combination with antineoplastic therapeutic agents, as well as pharmaceutical compositions designed for treating multidrug resistant cancers.
Career Highlights
Zhe-Sheng Chen is affiliated with St. John's University, where he continues to advance his research in cancer treatment. His work has garnered attention for its potential to improve outcomes for patients facing multidrug resistant cancers.
Collaborations
Some of his notable coworkers include Zhi Shi and Charles R Ashby, Jr. Their collaborative efforts contribute to the ongoing research and development in the field of cancer therapies.
Conclusion
Zhe-Sheng Chen's innovative work in the treatment of multidrug resistant cancers highlights the importance of research in overcoming significant medical challenges. His contributions through patenting and collaboration are paving the way for advancements in cancer treatment.